More downside before potential buy on CPRX

157
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.01 per share a year ago. wait for a decent retracement and buy.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.